axatilimab
axatilimab: developed by 1 company · 22 clinical trials tracked.
axatilimab evidence translation
What we can confirm
22 tracked trials
What it means
What to watch
Prepared research question
How could axatilimab → SNDX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Syndax Pharmaceuticals Inc (SNDX) Chronic Graft-versus-host-disease; Idiopathic Pulmonary Fibr… | Phase 2 |
Clinical Trials (22)showing 10 most recent
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Primary endpoint: Phase 2 Dose Level determination
IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Primary endpoint: Overall Response Rate (ORR)
A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Primary endpoint: Objective Response (OR) at 6 months
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Primary endpoint: Safety and Adverse Events (AEs)
Axatilimab for Sclerotic Chronic Graft-Versus-Host Disease
Primary endpoint: Overall response rate (ORR) in sclerotic manifestations
A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy
Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Primary endpoint: Objective Response (OR) at 6 months
A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Primary endpoint: Best Overall Response Rate (ORR)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Primary endpoint: Event Free Survival (EFS)
Frequently asked questions
Who is developing axatilimab?
axatilimab is being developed by Syndax Pharmaceuticals Inc.
How many clinical trials involve axatilimab?
BioSniper tracks 22 clinical trials involving axatilimab.